ISEC Healthcare Ltd

ISEC Healthcare Ltd maintains a strong liquidity position, with a current ratio of 1.72, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is high, supported by SGD 15.87 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.14 suggests a conservative capital structure, with total liabilities accounting for only 14% of total equity.

In terms of profitability, ISEC Healthcare Ltd reported a net income of SGD 3.4 million, translating to a return on equity (ROE) of 4.11% and a return on assets (ROA) of 3.14%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The operating margin of 25.3% is in line with the industry median, suggesting that the company is managing its operating costs effectively.

The company's revenue is primarily concentrated in its core pharmaceutical segment, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to regional economic or regulatory risks, particularly in the healthcare sector, which is subject to frequent policy changes.

Looking ahead, ISEC Healthcare Ltd is projected to experience a modest growth in revenue, with a year-over-year increase of approximately 100% in the current fiscal year. This growth is supported by a strong operating cash flow of SGD 7.4 million and a free cash flow of SGD 3.5 million, which can be reinvested into the business or used to pay down debt. However, the company's capital expenditure of SGD 4.26 million indicates ongoing investment in infrastructure and operations.

The risk assessment for ISEC Healthcare Ltd indicates a low probability of liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company's conservative debt structure and strong cash reserves further mitigate financial risk.

Recent events, including the latest financial filing, show a strong revenue performance, with the last actual revenue reported at SGD 36.98 million. This suggests that the company is on track to meet or exceed its financial targets, although no specific guidance or forward-looking statements were disclosed in the available data.

With a debt-to-equity ratio of 0.14, ISEC Healthcare maintains leverage well below the 0.32 cohort median, ensuring financial stability.

Revenue grew at a 4.2% CAGR over four years, showing consistent top-line expansion despite modest net income growth.

Low dilution, liquidity, and credit risk flags suggest a stable capital structure with minimal immediate financial distress indicators.

Long-term debt surged to SGD 29.4 million in FY2018, more than doubling from SGD 13.8 million in FY2015.

Net income declined by 1.1% year-over-year, indicating stagnation in bottom-line performance despite revenue growth.

Return on equity of 4.1% trails the 4.6% cohort median, suggesting less efficient capital utilization than peers.

Capex intensity is in the bottom quartile of the cohort, potentially indicating underinvestment in future growth drivers.

Revenue SGD 18.6M, +4,3% YoY; Operating income −9,0% YoY.

• ▍Revenue SGD 18.6M, +4,3% YoY
• ▍Operating income −9,0% YoY
• ▍Net income −8,1% YoY
• ▍Free cash flow −11,7% YoY
• ▍Net margin 15.2%

Revenue SGD 20.7M, +4,5% YoY; Operating income +11,2% YoY.

• ▍Revenue SGD 20.7M, +4,5% YoY
• ▍Operating income +11,2% YoY
• ▍Net income +33,5% YoY
• ▍Free cash flow +46,2% YoY
• ▍Net margin 12.8%

Revenue SGD 79.2M, +6,8% YoY; Operating income +3,1% YoY.

• ▍Revenue SGD 79.2M, +6,8% YoY
• ▍Operating income +3,1% YoY
• ▍Net income +4,2% YoY
• ▍Free cash flow −262,7% YoY
• ▍Net margin 16.9%

Revenue SGD 63.0M, +55,6% YoY; Operating income +82,5% YoY.

• ▍Revenue SGD 63.0M, +55,6% YoY
• ▍Operating income +82,5% YoY
• ▍Net income +81,3% YoY
• ▍Free cash flow +651,2% YoY
• ▍Net margin 19.9%